Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-03-01

FDA Approved: FARXIGA — Supplemental Application (AstraZeneca Pharmaceuticals LP)

View source ↗

Summary

The FDA approved a supplemental application for Farxiga (dapagliflozin) from AstraZeneca Pharmaceuticals LP. This action updates the drug's labeling to reflect …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • FARXIGA (dapagliflozin)

Snippet

SUPPL AP for FARXIGA (DAPAGLIFLOZIN)